Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 365 participants.
Also called NCT01652729
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 365 participants
- Sponsor
- Registry
-
NCT01652729
-
- Other papers using this trial's data
- Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01652729. Randomized; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-04-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
- Acronym
- DURATION-NEO-2
- Condition
- Diabetes Type 2
- Intervention (Drug)
- Exenatide once weekly suspension
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01652729- Content hash
6c1a0126e9156b3c5dc82eea5751893ebee6f4c239f7c6e1a61a2cf2a1fa3590